Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.43 |
| ▸ | ULK1 | O75385 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25360845 | 1.00 | BTK (0.43) | BTKULK1JAK3JAK1LRRK2 | |
| SCHEMBL30456552 | 0.85 | ULK1 (0.45) | ULK1LRRK2MAPK3 | |
| SCHEMBL25362137 | 0.85 | ULK1 (0.45) | ULK1LRRK2MAPK3 | |
| SCHEMBL24087383 | 0.82 | ULK1 (0.47) | ULK1MAPK3EPHX2 | |
| SCHEMBL30456591 | 0.82 | HCRTR1 (0.43) | BTKJAK1JAK2KDM1AMAOB | |
| SCHEMBL30842076 | 0.80 | BTK (0.41) | BTKJAK3JAK1JAK2KDM1A | |
| SCHEMBL22901094 | 0.79 | IDH1 (0.49) | ULK1JAK1MAPK3L3MBTL1 | |
| SCHEMBL29821059 | 0.79 | IDH1 (0.49) | ULK1JAK1MAPK3L3MBTL1 | |
| SCHEMBL6460434 | 0.79 | MCHR1 (0.48) | ULK1JAK3MERTKCKS1BSKP1 | |
| SCHEMBL6460431 | 0.79 | MCHR1 (0.48) | ULK1JAK3MERTKCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145632-A1 | Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine | INSILICO MEDICINE IP LIMITED (HK) | 2025-05-08 | — | — | US | disclosed |
| EP-4455132-A1 | PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Insilico Medicine IP Limited (HK) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023116761-A1 | PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 英矽智能科技知识产权有限公司 | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145632-A1 | Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine | DPYD, TYMP, NUDT1 | BTK 162/4885ULK1 2923/4885JAK3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.